Biology and Treatment of Rhabdoid Tumor
- 1 January 2015
- journal article
- review article
- Published by Begell House Inc. Publishers in Critical Reviews™ in Oncogenesis
- Vol. 20 (3-4) , 199-216
Abstract
Rhabdoid tumor is a rare, highly aggressive malignancy that primarily affects infants and young children. These tumors typically arise in the brain and kidney, although extrarenal, non−central nervous system tumors in almost all soft-tissue sites have been described. SMARCB1 is a member of the SWI/SNF chromatin-remodeling complex and functions as a tumor suppressor in the vast majority of rhabdoid tumors. Patients with germline mutations or deletions affecting SMARCB1 are predisposed to the development of rhabdoid tumors, as well as the genetic disorder schwannomatosis. The current hypothesis is that rhabdoid tumors are driven by epigenetic dysregulation, as opposed to the alteration of a specific biologic pathway. The strategies for novel therapeutic approaches based on what is currently known about rhabdoid tumor biology are presented.Keywords
This publication has 99 references indexed in Scilit:
- Haploinsufficiency of ARID1B, a Member of the SWI/SNF-A Chromatin-Remodeling Complex, Is a Frequent Cause of Intellectual DisabilityThe American Journal of Human Genetics, 2012
- Initial testing of the CENP‐E inhibitor GSK923295A by the pediatric preclinical testing programPediatric Blood & Cancer, 2011
- Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumorsPediatric Blood & Cancer, 2010
- Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: A children's oncology group studyPediatric Blood & Cancer, 2010
- Initial testing of topotecan by the pediatric preclinical testing programPediatric Blood & Cancer, 2010
- Germline Nonsense Mutation and Somatic Inactivation of SMARCA4/BRG1 in a Family with Rhabdoid Tumor Predisposition SyndromeThe American Journal of Human Genetics, 2010
- Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)Pediatric Blood & Cancer, 2010
- High-dose chemotherapy and autologous stem cell rescue for atypical teratoid/rhabdoid tumor of the central nervous systemJournal of Neuro-Oncology, 2009
- Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing programPediatric Blood & Cancer, 2009
- Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing programPediatric Blood & Cancer, 2009